Analysis of urinary caffeine metabolites to assess biotransformation enzyme activities by reversed-phase high-performance liquid chromatography
- PMID: 9653923
- DOI: 10.1016/s0378-4347(98)00016-4
Analysis of urinary caffeine metabolites to assess biotransformation enzyme activities by reversed-phase high-performance liquid chromatography
Abstract
An isocratic high-performance liquid chromatography procedure was developed for the analysis of five urinary metabolites of caffeine; caffeine or 1,3,7-trimethylxanthine (137X), paraxanthine or 1,7-dimethylxanthine (17X), 1,7-dimethylurate (17U), 1-methylxanthine (1X), 1-methylurate (1U) and 5-acetylamino-6-formylamino-3-methyluracil (AFMU). A standardized procedure was used for oral intake of caffeine and for urine collection. Conditions for sample storage and preparation were optimized, resulting in no detectable loss of caffeine metabolites after storage of the urine samples for four months. Urine samples were extracted with chloroform-2-propanol (4:1, v/v) and separated on a reversed-phase column with acetic acid (33%)-tetrahydrofuran-acetonitrile-water (1:2.5:44:925.5, v/v) as the eluent. Peaks were monitored at 280 nm. Peak heights were measured and the five metabolites were quantified using calibration curves. Cytochrome P4501A2 (CYP1A2) activity was calculated from the molar ratio (AFMU+1X+1U)/17U, N-acetyltransferase (NAT) from the ratio AFMU/1X, XO from the ratio 1U/1X+1U and cytochrome P4502A6 (CYP2A6) from the ratio 17U/(17U+17X+1U+ 1X+AFMU). The inter-assay coefficients of variation ranged from 1.7% for 17U to 5.7% for IX. The intra-individual variation in metabolite ratios determined in two people, with intervals of a few days to several weeks between measurements, ranged from 2. 1% for XO to 11.0% for CYP2A6. Using this procedure, metabolic ratios were determined for four groups of subjects; healthy, non-smoking females using oral contraceptives (OC users, n=5) and non-users (n=5), healthy nonsmoking males (n=9) and children (n=7). Results found in this study were comparable to results reported in the literature for subjects with similar characteristics. A significantly higher CYP1A2 ratio was found for males (4.87+/-0.47) compared to females (3.62+/-0.91: p=0.005, Mann-Whitney). For the other enzyme activities, no significant differences were found between the groups of subjects in this study.
Similar articles
-
In vivo evaluation of CYP1A2, CYP2A6, NAT-2 and xanthine oxidase activities in a Greek population sample by the RP-HPLC monitoring of caffeine metabolic ratios.Biomed Chromatogr. 2007 Feb;21(2):190-200. doi: 10.1002/bmc.736. Biomed Chromatogr. 2007. PMID: 17221922
-
Caffeine metabolism before and after liver transplantation.Int J Clin Pharmacol Ther. 2001 Feb;39(2):53-60. doi: 10.5414/cpp39053. Int J Clin Pharmacol Ther. 2001. PMID: 11270802
-
Relationship between the severity of alcoholic liver cirrhosis and the metabolism of caffeine in 226 patients.Int J Clin Pharmacol Ther. 2000 Oct;38(10):467-75. doi: 10.5414/cpp38467. Int J Clin Pharmacol Ther. 2000. PMID: 11073287
-
Caffeine metabolic ratios for the in vivo evaluation of CYP1A2, N-acetyltransferase 2, xanthine oxidase and CYP2A6 enzymatic activities.Curr Drug Metab. 2009 May;10(4):329-38. doi: 10.2174/138920009788499003. Curr Drug Metab. 2009. PMID: 19519341 Review.
-
The use of caffeine as a metabolic probe for human drug metabolizing enzymes.Gen Pharmacol. 1996 Mar;27(2):245-9. doi: 10.1016/0306-3623(95)02014-4. Gen Pharmacol. 1996. PMID: 8919637 Review.
Cited by
-
Altered xanthine oxidase and N-acetyltransferase activity in obese children.Br J Clin Pharmacol. 2011 Jul;72(1):109-15. doi: 10.1111/j.1365-2125.2011.03959.x. Br J Clin Pharmacol. 2011. PMID: 21382071 Free PMC article.
-
Structure-Bioactivity Relationships of Methylxanthines: Trying to Make Sense of All the Promises and the Drawbacks.Molecules. 2016 Jul 27;21(8):974. doi: 10.3390/molecules21080974. Molecules. 2016. PMID: 27472311 Free PMC article. Review.
-
Nicotine chemistry, metabolism, kinetics and biomarkers.Handb Exp Pharmacol. 2009;(192):29-60. doi: 10.1007/978-3-540-69248-5_2. Handb Exp Pharmacol. 2009. PMID: 19184645 Free PMC article. Review.
-
Coffee intake, variants in genes involved in caffeine metabolism, and the risk of epithelial ovarian cancer.Cancer Causes Control. 2009 Apr;20(3):335-44. doi: 10.1007/s10552-008-9247-1. Epub 2008 Oct 21. Cancer Causes Control. 2009. PMID: 18941913 Free PMC article.
-
Clinically significant pharmacokinetic interactions between dietary caffeine and medications.Clin Pharmacokinet. 2000 Aug;39(2):127-53. doi: 10.2165/00003088-200039020-00004. Clin Pharmacokinet. 2000. PMID: 10976659 Review.
MeSH terms
Substances
LinkOut - more resources
Medical